The involvement of patients' organizations in the Board of ERN-EuroBloodNet has been assured in order to guarantee their pivotal role within the network and keep ERN-EuroBloodNet patients' centred approach. The ERN-EuroBloodNet European Patient Advocacy Group (ePAG) is formed by 9 different patients Advocates who represent their disease area in the ERN-EuroBloodNet as well as the interests of the wider patient community affected by rare haematological diseases.
Maria Piggin, ePAG representative of Paroxysmal Nocturnal Haemoglobinuria (PNH Support) in ERN-EuroBloodNet, has recently published an article focused on the perspective on Biosimilars as a Patients Advocate and patient.
We invite you to read the article entitled, Addressing Inequality of Access to Biologics: What Is Your Role? A Patient (Advocate)'s Perspective on Biosimilars that has been published on HemaSphere.